Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now
Executive Summary
FDA's approval of Merck's Keytruda/chemo combo based on Phase II data secures the company's position in the prized first-line lung cancer indication, but Phase III readouts from other combination trials are right around the corner.
You may also be interested in...
Keeping Track: Novel Approvals For Diacomit, Takhzyro And Oxervate; CRLs For Mallinckrodt And Allergan
The latest drug development news and highlights from our US FDA Performance Tracker.
Merck's Keytruda Monotherapy May Get Stuck With Small Role In First-line Lung Cancer
As results for KEYNOTE-042 are reported at ASCO, Merck's Roy Baynes says Keytruda plus chemotherapy is the standard of care in first-line non-small cell lung cancer, but Keytruda monotherapy is an option for those who don't tolerate chemo well and/or don't have very active disease.
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.